- Home
- CINT vs AKBA Comparison
CINT vs AKBA Comparison
Compare CINT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- AKBA
- Stock Information
- Founded
- CINT 1995
- AKBA 2007
- Country
- CINT Brazil
- AKBA United States
- Employees
- CINT N/A
- AKBA N/A
- Industry
- CINT EDP Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- AKBA Health Care
- Exchange
- CINT Nasdaq
- AKBA Nasdaq
- Market Cap
- CINT 672.1M
- AKBA 669.7M
- IPO Year
- CINT 2021
- AKBA 2014
- Fundamental
- Price
- CINT $5.83
- AKBA $3.22
- Analyst Decision
- CINT Buy
- AKBA Strong Buy
- Analyst Count
- CINT 8
- AKBA 4
- Target Price
- CINT $7.54
- AKBA $6.63
- AVG Volume (30 Days)
- CINT 298.2K
- AKBA 5.0M
- Earning Date
- CINT 05-13-2025
- AKBA 05-08-2025
- Dividend Yield
- CINT N/A
- AKBA N/A
- EPS Growth
- CINT 53.80
- AKBA N/A
- EPS
- CINT 0.24
- AKBA N/A
- Revenue
- CINT $444,135,000.00
- AKBA $184,909,000.00
- Revenue This Year
- CINT $526.48
- AKBA $21.58
- Revenue Next Year
- CINT $13.35
- AKBA $47.69
- P/E Ratio
- CINT $24.93
- AKBA N/A
- Revenue Growth
- CINT 3.04
- AKBA N/A
- 52 Week Low
- CINT $4.29
- AKBA $0.80
- 52 Week High
- CINT $8.04
- AKBA $3.14
- Technical
- Relative Strength Index (RSI)
- CINT 49.27
- AKBA 71.83
- Support Level
- CINT $5.80
- AKBA $2.76
- Resistance Level
- CINT $6.30
- AKBA $3.14
- Average True Range (ATR)
- CINT 0.40
- AKBA 0.14
- MACD
- CINT -0.05
- AKBA 0.02
- Stochastic Oscillator
- CINT 37.84
- AKBA 86.71
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.